| Document |
Document Title |
|
WO/2022/109684A1 |
A dosage form for oral delivery of a therapeutic agent to a subject, the dosage form comprising: (i) a lipid nanocarrier formulation, the lipid nanocarrier formulation comprising the therapeutic agent, and lipids in the form of a mesopha...
|
|
WO/2022/115502A1 |
The present disclosure relates to treatment of bleeding disorders, in particular, hemophilia A (mild, moderate or severe hemophilia) and von Willebrand disease (VWD), Type 1 or Type 2 or Type 3, using VWF targeting agents such as a PEGyl...
|
|
WO/2022/106425A1 |
The invention relates to the treatment or prevention of liver failure.
|
|
WO/2022/109161A1 |
The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing one or more disease states that could benefit...
|
|
WO/2022/109328A1 |
The present invention relates to compositions of peptide inhibitors of the interleukin-23 receptor (IL-23R) or pharmaceutically acceptable salt or solvate forms thereof, corresponding pharmaceutical compositions, methods and/or uses for ...
|
|
WO/2022/105725A1 |
Disclosed is a preparation method for deer velvet alcohol. The method comprises: freeze-drying fresh deer velvet, adding same into a 40-53 ° alcohol base at a 1:20-500 ratio, utilizing ultrasonic reflux extraction, and after centrifugat...
|
|
WO/2022/105877A1 |
Disclosed are a pharmaceutical composition comprising a bilobalide component and a pharmaceutically acceptable carrier or excipient, and a pharmaceutical preparation of a bilobalide component comprising a bilobalide component, a pharmace...
|
|
WO/2022/109421A1 |
Provided herein are compositions and methods for inducing cell death in a regulated manner, for example in a safety switch system. Inducible cell death can be triggered by ligand binding to a one or more ligand binding domains. Cell deat...
|
|
WO/2022/108148A1 |
The present invention relates to an ADAMTS13 mutant protein having an improved escaping rate against an autoantibody and a composition for preventing or treating thrombotic diseases using same. By efficiently avoiding representative auto...
|
|
WO/2022/105041A1 |
Provided is an application of an miR-325 nucleic acid analog in the preparation of a related product for treating sinusoidal endothelial cell pathological dysfunction. By directly or indirectly affecting signal pathways by means of miR-3...
|
|
WO/2022/104345A1 |
The present disclosure relates to l-(2-(4-cyclopropyl-lH-l,2,3- triazol-l-yl)acetyl)-4-hydroxypyrrolidine-2-carboxamide derivatives and structurally related compounds of formula (I) as VHL inhibitors for the treatment of e.g. anemia (e.g...
|
|
WO/2022/103239A1 |
The present invention relates to a preparation method for edoxaban tosylate or a hydrate thereof and, more specifically, is characterized by the reaction reaction of edoxaban with p-toluene sulfonic acid or a hydrate thereof at room temp...
|
|
WO/2022/101501A1 |
A composition for use in a therapeutic method of treatment or prevention of hyperuricaemia, gout and/or renal impairment, said composition comprising: A) serine, glycine, betaine, N-acetylglycine, N-acetylserine, dimethylglycine, sarcosi...
|
|
WO/2022/102740A1 |
The purpose of the present invention is to provide a drug or a food composition for decreasing a neutrophil-to-lymphocyte ratio. Provided is an agent for decreasing a neutrophil-to-lymphocyte ratio in blood, which contains a curcumin c...
|
|
WO/2022/100741A1 |
Provided is a fusion protein of human serum albumin or a wild type thereof and human interleukin-2 or a mutation thereof, said fusion protein has a significantly extended in vivo half-life relative to recombinant interleukin-2, can be us...
|
|
WO/2022/103411A1 |
The present disclosure relates to 1-(2-(4-cyclopropyl-1H-l,2,3- triazol-l-yl)acetyl)-4-hydroxy-N-(benzyl)pyrrolidine-2-carbo
xamide derivatives and structurally related compounds as VHL inhibitors for the treatment of e.g. anemia (e.g. c...
|
|
WO/2022/101395A1 |
The invention relates to a bradykinin (BK) B2-receptor antagonist having structural fomula (I) for use in prophylactic treatment of angioedema (AE) or in a method of treating AE, wherein said compound is at least once orally administered...
|
|
WO/2022/101840A1 |
The present disclosure generally relates to the field of fortification of food with iron. More particularly, the present disclosure relates to an irregular and porous elemental iron powder, which is suitable for fortifying food and pharm...
|
|
WO/2022/097837A1 |
The present invention relates to a composition for suppressing side effects of amlodipine, the composition being capable of maximizing the effects of hypertension treatment by effectively reducing side effects caused by a toxic dose and ...
|
|
WO/2022/096547A1 |
Acute chest syndrome (ACS) is a common and potentially lethal form of acute lung injury in sickle cell disease (SCD). Because pathophysiology remains unclear, therapeutic options are limited to supportive care with empiric antibiotics an...
|
|
WO/2022/096424A1 |
The invention relates to nucleic acid products that interfere with or inhibit PROS1 gene expression. It further relates to therapeutic uses of PROS1 inhibition for the treatment of bleeding disorders.
|
|
WO/2022/098877A1 |
In certain aspects, the present disclosure provides dosing regimens, dosing forms, and formulations comprising a recombinant fusion protein comprising human activin receptor type- II (ActRII) polypeptides or derivatives thereof linked to...
|
|
WO/2022/096549A1 |
The present invention relates to a stable hydrate of clazosentan disodium salt, pharmaceutical formulations manufactured using the same and their use as medicaments.
|
|
WO/2022/095965A1 |
Disclosed in the present invention is a tetrazole derivative having a structure represented by a general formula I. Also disclosed in the present invention are a composition containing the tetrazole derivative and an application of the t...
|
|
WO/2022/098812A1 |
The invention features methods of treating iron overload in a subject by administering BMP or hepcidin inhibitors, such as ALK2 inhibitors. The invention also features methods of decreasing iron levels in a subject by administering BMP o...
|
|
WO/2022/090490A1 |
Pharmaceutical composition comprising rifaximin, a hydrogenated castor oil, and at least one additional solubilizing excipient for use in the treatment of sickle cell disease, vaso-occlusive crises or circulating ages neutrophils.
|
|
WO/2022/090482A1 |
Provided herein are pharmaceutical compositions comprising 15-HETrE and methods of using the same to treat a variety of conditions and disorders.
|
|
WO/2022/092310A1 |
The present invention provides a compound, etc. which has aldehyde dehydrogenase 2 (ALDH2) activating activity. Provided are a compound represented by formula (1), a pharmaceutically acceptable salt thereof, and a prodrug thereof. [In th...
|
|
WO/2022/089677A1 |
Antiviral antithrombotic and tumor-toxic composition containing an arginine as the first ingredient and containing thiocyanate, also called rhodanide, as the second ingredient, namely in the form of a potassium thiocyanate or in the form...
|
|
WO/2022/087058A1 |
The present invention relates to nanoparticles complexed with N-2-benzothiazolyl-4-[[(2-hydroxy-3-methoxyphenyl)methyl]ami
no]-benzenesulfonamide (ML355) configured for treating cardiovascular related disorders. In particular, the presen...
|
|
WO/2022/083706A1 |
Provided are a series of salts of FXIa inhibitor compounds, pharmaceutical compositions containing said compounds, and a use of said compounds in drugs for the treatment of diseases such as thromboembolism.
|
|
WO/2022/083707A1 |
Provided is a pharmaceutical use of an FXIa inhibitor compound or a salt thereof. Specifically, provided is a use of the FXIa inhibitor compound or the salt thereof in preparation of drugs for prevention and/or treatment of arterial and ...
|
|
WO/2022/085781A1 |
Provided is a new means for recovery from a hematopoietic disorder. An agent for promoting recovery from a hematopoietic disorder that includes a compound represented by formula (I) or a salt thereof. {In the formula, each symbol is as...
|
|
WO/2022/084693A1 |
The present invention relates to treatments of bradykinin-mediated angioedema. In particular, the present invention provides on-demand treatments of bradykinin-mediated angioedema by orally administering a plasma kallikrein inhibitor to ...
|
|
WO/2022/080798A1 |
The present invention relates to a controlled release formulation containing nafamostat or a pharmaceutically acceptable salt thereof, and to a method for preparing same. As a sustained release tablet according to one aspect may simultan...
|
|
WO/2022/078354A1 |
Disclosed in the present invention is the use of a ligustrazine nitrone compound in the preparation of a drug for preventing and/or treating renal anemia, wherein the ligustrazine nitrone compound is a compound having a structure as repr...
|
|
WO/2022/081742A1 |
Disclosed herein are methods of treating a complication of a hemoiysis and/or an inflammasome activation-associated disease comprising administering to a patient in need thereof quinine, or a derivative or sait thereof, or the combinatio...
|
|
WO/2022/081997A1 |
The present disclosure relates generally to methods of preventing, reducing risk of developing, or treating a blood disorder (e.g., cold agglutinin hemolytic anemia (cold agglutinin disease), cold antibody hemolytic anemia, ABO incompati...
|
|
WO/2022/072397A1 |
This disclosure to methods for treating or preventing particular symptoms and disorders which are associated with blood disorders using AMPK activators. Also disclosed are pharmaceutical composition comprising an AMPK activator for use i...
|
|
WO/2022/069576A1 |
The invention relates generally to biotechnology and medicine and to sources and salts of autophagy inhibiting peptides useful as pharmaceutical compounds. In particular, the invention provides method for reducing formyl-peptide-receptor...
|
|
WO/2022/067394A1 |
The present invention provides humanized antibody fragment (scFv) from murine clone IV.3 scFv that specifically binds FcyRIIA, with a linker between the VH and VL with the amino acid sequence W A W V WLTET A V, which linker also binds Fc...
|
|
WO/2022/072475A1 |
A therapeutic hemoglobin-based oxygen carrier solution is described for treating poisoning caused by cyanide and/or carbon monoxide. The solution comprises a combination of oxidized hemoglobin-based oxygen carrier and a reduced hemoglobi...
|
|
WO/2022/072439A1 |
A method of preparing an iron hydroxide product is provided. The method includes the steps of: adding a first base solution to a solution of a ferric salt to obtain Mixture A having a pH value of 2.7-2.8, adding a second base solution to...
|
|
WO/2022/067502A1 |
The present invention provides a nicotinic acid derivative A-type compound having anti-inflammatory activity. The structure of the compound is represented by the general formula (I), wherein R1 and R2 are different substitution sites of ...
|
|
WO/2022/067773A1 |
Provided is an active polypeptide, the sequence being VAPEEHPVLL. The polypeptide has anticoagulation and antiplatelet aggregation effects, and exhibits significant activity in the anticoagulation (APTT, PT and TT) and inhibition of ADP-...
|
|
WO/2022/067503A1 |
Provided in the present invention is a nicotinic acid derivative B having an anti-inflammatory and immunosuppressive activity, and the structural general formula thereof is I, wherein, R1 and R2 are different substitution sites on a main...
|
|
WO/2022/071896A1 |
The invention discloses novel pharmaceutically acceptable salts of eltrombopag and process for preparing the same. The invention also relates to solid state forms of eltrombopag sesquiethanolamine and processes for the preparation thereo...
|
|
WO/2022/069416A1 |
The present invention relates to a composition comprising the association of the molecules of flavanol and epsilon-viniferin monomers as a nutritional product or a drug for humans or animals.
|
|
WO/2022/073041A2 |
A dual functional expression vector is disclosed. The dual functional vector comprises a nucleic acid suitably configured for expressing at least two active agents, where a first active agent is an siRNA/shRNA or miRNA for silencing endo...
|
|
WO/2022/072334A1 |
A method of making sterile diploid organisms includes mating a first population and a second population of single knock-in diploid organisms, wherein the first population of single knock-in diploid organisms are heterozygous organisms ex...
|
